2022年美国风湿病学会/美国髋膝关节外科医师协会指南:风湿病患者择期全髋或全膝关节置换术围手术期抗风湿药物管理
该指南由风湿病学家、骨科外科医生和感染病专家组成的小组制定,采用GRADE方法对证据质量和推荐强度进行评级。指南更新了2017年建议,涵盖传统改善病情抗风湿药、生物制剂、靶向合成小分子药物和糖皮质激素在成人炎症性关节炎(包括类风湿关节炎和脊柱关节炎)、幼年特发性关节炎或系统性红斑狼疮患者择期全髋或全膝关节置换术围手术期的继续、暂停和重启时机及糖皮质激素的最佳围手术期剂量。
要点
- 指南涵盖传统改善病情抗风湿药、生物制剂、靶向合成小分子药物和糖皮质激素的围手术期管理。
- 适用人群为炎症性关节炎(含类风湿关节炎和脊柱关节炎)、幼年特发性关节炎或系统性红斑狼疮行择期全髋或全膝关节置换术的成人患者。
- 指南更新了药物继续、暂停和重启时机的建议以及糖皮质激素的最佳围手术期剂量。
核心结论
- 该更新指南纳入了近期引入的免疫抑制药物,帮助临床医生和患者在炎症性关节炎和系统性红斑狼疮患者择期全髋或全膝关节置换术时进行围手术期改善病情药物管理决策。
研究设计与样本
- 召集风湿病学家、骨科外科医生和感染病专家组成小组,更新系统文献综述,纳入针对临床相关人群、干预、对照和结局(PICO)问题的现有药物。
- 采用推荐分级的评估、制定与评价(GRADE)方法,通过小组共识过程对证据质量和推荐强度进行评级。
主要发现
- 该指南更新了2017年关于围手术期使用改善病情抗风湿疗法的建议,涵盖传统改善病情抗风湿药、生物制剂、靶向合成小分子药物和糖皮质激素。
- 适用人群为成人风湿病患者,具体为炎症性关节炎(包括类风湿关节炎和脊柱关节炎)、幼年特发性关节炎或系统性红斑狼疮患者,行择期全髋或全膝关节置换术。
- 指南更新了关于何时继续、何时暂停和何时重启这些药物的建议以及糖皮质激素的最佳围手术期剂量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop updated guidelines for the perioperative management of disease-modifying medications for patients with rheumatic diseases, specifically those with inflammatory arthritis (IA) and those with systemic lupus erythematosus (SLE), undergoing elective total hip arthroplasty (THA) or elective total knee arthroplasty (TKA). METHODS: We convened a panel of rheumatologists, orthopedic surgeons, and infectious disease specialists, updated the systematic literature review, and included currently available medications for the clinically relevant population, intervention, comparator, and outcomes (PICO) questions. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence and the strength of recommendations using a group consensus process. RESULTS: This guideline updates the 2017 recommendations for perioperative use of disease-modifying antirheumatic therapy, including traditional disease-modifying antirheumatic drugs, biologic agents, targeted synthetic small-molecule drugs, and glucocorticoids used for adults with rheumatic diseases, specifically for the treatment of patients with IA, including rheumatoid arthritis and spondyloarthritis, those with juvenile idiopathic arthritis, or those with SLE who are undergoing elective THA or TKA. It updates recommendations regarding when to continue, when to withhold, and when to restart these medications and the optimal perioperative dosing of glucocorticoids. CONCLUSION: This updated guideline includes recently introduced immunosuppressive medications to help decision-making by clinicians and patients regarding perioperative disease-modifying medication management for patients with IA and SLE at the time of elective THA or TKA.
引用
- Goodman SM, Springer BD, Chen AF, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Care Res (Hoboken). 2022. PMID: 35718887. doi:10.1002/acr.24893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。